Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
OZEM ETF — Roundhill GLP-1 & Weight Loss ETF
Roundhill GLP-1 & Weight Loss ETF (OZEM)
Updated November 17, 2026.
Verdict as of November 17, 2026 close
OZEM's distribution is rated unproven by the Dividend Vision Distribution Safety Score™ (50/100, medium confidence). The latest total cash payment per current share, $0.41 with an ex-date of December 30, 2025, was 673.6% higher than the previous $0.053. It is not yet confirmed whether this is an increase in the regular payout or a one-off difference.
Sources: Roundhill Investments page for OZEM, Section 19a-1 notices, scoring methodology.
OZEM is an ETF linked to GLP-1 & weight-loss drug ecosystem (actively managed). Its trailing-12-month yield is 1.35%, its expense ratio is 0.59%. Dividend Vision Distribution Safety Score™ is 50/100 (Unproven). Total return is 12.3% over the past 2.2 years, 26.8 points behind SPY at 39.1%.
Roundhill GLP-1 & Weight Loss ETF is an actively managed equity fund that invests at least 80% of its assets in companies involved in the GLP-1 and weight-loss drug ecosystem, including through derivative instruments, and is non-diversified. The fund has a modest current distribution rate with annual distributions and carries an expense ratio of 0.59%; note that the latest distribution was special and may not recur regularly. The fund appeals to investors seeking exposure to the GLP-1 and weight-loss pharmaceutical sector.
OZEM dividend yield and income
Price as of 2026-11-17.
Trailing-12-month yield (1.35%) is the last year of cash distributions by ex-date divided by the current price. The dividend amount is $0.409914. The ex-dividend date is 12/30/2025. The payment date is 12/31/2025.
| Ex-date | Amount | Change from previous payment |
|---|---|---|
| 2025-12-30 | $0.41 | 673.6% Total cash (unclassified) |
| 2024-12-30 | $0.053 | — |
| 2024 total (partial launch year) | $0.053 | — |
| 2025 total | $0.41 | — |
OZEM holdings and sector exposure
The top 10 holdings are 67.7% of the fund.
| Ticker | Name | Weight |
|---|---|---|
| LLY | Eli Lilly and Company | 15.03% |
| NVO | Novo Nordisk A/S | 11.23% |
| PFE | Pfizer Inc | 7.90% |
| KLRA | Kailera Therapeutics, Inc. Common Stock | 5.72% |
| 1093 | CSPC Pharmaceutical Group Ltd | 5.26% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | 5.10% |
| AMGN | Amgen Inc | 4.70% |
| VKTX | Viking Therapeutics Inc | 4.64% |
| AZN | AstraZeneca PLC | 4.43% |
| 128940 | Hanmi Pharm Co Ltd | 3.69% |
To see how this fund's sectors add up across your own holdings, use True Exposure.
OZEM performance versus SPY
Total return is 12.3% over the past 2.2 years, 26.8 points behind SPY at 39.1%. Over the past year its total return — price change plus distributions reinvested — is -4.5%. Its deepest 1-year drawdown was 22.4%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | 3.9% | — |
| 3M | -8.0% | — |
| 6M | -1.5% | — |
| YTD | -11.0% | — |
| 1Y | -4.5% | — |
| 2Y CAGR | — | 10.40% |
| Since inception 2024-09-06 · 2.2 years | 12.3% | 5.40% |
OZEM key facts
- Distribution Safety Score™
- 50 · Unproven
- Issuer
- Roundhill Investments
- Asset type
- ETF
- Asset class
- Equity
- Inception date
- 09/06/2024
- Expense ratio
- 0.59%
- Distribution frequency
- Annual
- Trailing yield
- 1.35%
- Last close
- $30.39 (as of 2026-11-17)
- AUM
- $55,848,214 (as of 2026-11-17)
- Average volume
- 6,593
- Dividend
- $0.409914
- Ex-dividend date
- 12/30/2025
- Payment date
- 12/31/2025
- Beta
- 0.7674
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) has no calculation basis on file. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (1.35%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: Roundhill Investments or company page; Index: GLP-1 & weight-loss drug ecosystem (actively managed); prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
OZEM risks and drawbacks
Payments are annual, so cash flow is lumpy versus a monthly fund. Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 22.4%.
Who may consider OZEM — and who may not
It is a weaker fit for investors who need monthly cash flow (OZEM pays annual); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on OZEM
- ETFs going ex-dividend this week
- Roundhill Investments upcoming distributions
- All tickers starting with O
Frequently asked questions
Does OZEM pay monthly?
No. OZEM currently pays annual, not monthly.
What is OZEM linked to?
OZEM is linked to GLP-1 & weight-loss drug ecosystem (actively managed), not a broad market index.
What is OZEM's expense ratio?
OZEM's expense ratio is 0.59%.
When does OZEM pay a dividend?
OZEM pays annual. The dividend amount is $0.409914. The ex-dividend date is 12/30/2025. The payment date is 12/31/2025.
How has OZEM performed?
Total return is 12.3% over the past 2.2 years, 26.8 points behind SPY at 39.1%. Over the past year its total return — price change plus distributions reinvested — is -4.5%. Its deepest 1-year drawdown was 22.4%.
Is OZEM a good investment?
OZEM's Dividend Vision Distribution Safety Score is 50 (Unproven). That is a risk signal, not investment advice. Compare peers below rather than treating any single figure as a buy or sell.
More securities from Roundhill Investments.
Tickers
OZEM's distribution is rated unproven by the Dividend Vision Distribution Safety Score™ (50/100, medium confidence). The latest total cash payment per current share, $0.41 with an ex-date of December 30, 2025, was 673.6% higher than the previous $0.053. It is not yet confirmed whether this is an increase in the regular payout or a one-off difference.
Sources: Roundhill Investments page for OZEM, Section 19a-1 notices, scoring methodology.
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.